Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: a Real-World Study

被引：6

作者：

Civera, Jose ^{[1
,2
]}

de la Espriella, Rafael ^{[1
,2
,3
]}

Heredia, Raquel ^{[1
,2
]}

Minana, Gema ^{[1
,2
,3
]}

Santas, Enrique ^{[1
,2
]}

Conesa, Adriana ^{[1
,2
]}

Mollar, Anna ^{[1
,2
]}

Sastre, Clara ^{[1
,2
]}

Martinez, Ana ^{[1
,2
]}

Villaescusa, Amparo ^{[1
,2
]}

Nunez, Julio ^{[1
,2
,3
]}

机构：

[1] Univ Valencia, Dept Cardiol, INCLIVA, Hosp Clin, Av Blasco Ibanez 17, Valencia 46010, Spain

[2] Univ Valencia, Dept Med, Valencia, Spain

[3] CIBER Cardiovasc Dis CIBERCV, Madrid, Spain

来源：

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH | 2022年 / 15卷 / 03期

关键词：

Worsening heart failure; Subcutaneous furosemide; Urinary sodium; Diuretics; Fluid overload; EUROPEAN-SOCIETY; ASSOCIATION; MANAGEMENT; CARDIOLOGY; THERAPY;

D O I：

10.1007/s12265-021-10173-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We aimed to evaluate the efficacy (short-term changes in surrogates of decongestion) and safety following the ambulatory administration of subcutaneous furosemide (SCF) in patients with WHF. Fifty-five ambulatory patients were treated with SCF administered by an elastomeric pump for at least 72 h. Surrogates of congestion were assessed at baseline, 72 h, and 30 days. Spot urinary sodium (uNa+) was assessed at baseline, 24-48-72 h, and 30 days. The median (IQI) of NT-proBNP and uNa+ at baseline was 5218 pg/mL (2856-10878) and 68 +/- 3 mmol/L, respectively. Following administration of SCF (median dose of 100 mg/daily), we found a sustained increase in uNa+ during the first 72 h of treatment compared to baseline, paralleled with evidence of decongestion at 72 h, and 30 days. No significant safety concerns were observed. SCF was an effective and safe diuretic strategy for outpatient congestion management.

引用

页码：644 / 652

页数：9

共 19 条

[1]

Adin DB, 2003, J VET INTERN MED, V17, P724, DOI 10.1892/0891-6640(2003)017<0724:SCOFWC>2.3.CO

[2]

[3] Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review [J].